Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 3/20 | 0.38 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.37 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.35 |
| ▸ | KLKB1 | P03952 | 7/20 | 0.35 |
| ▸ | PYGL | P06737 | 4/20 | 0.35 |
| ▸ | BACE1 | P56817 | 1/20 | 0.35 |
| ▸ | DPP4 | P27487 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | KLK1 | P06870 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1623568 | 0.80 | F10 (0.50) | F10DPP4 | |
| SCHEMBL1624371 | 0.79 | CFD (0.43) | SMYD3DPP4 | |
| SCHEMBL1628215 | 0.77 | F10 (0.37) | F10SMYD3PYGLDPP4HPGD | |
| SCHEMBL1621771 | 0.75 | KCNA3 (0.40) | F10SMYD3PYGLDPP4KLK1 | |
| SCHEMBL6825848 | 0.71 | KDM4E (0.35) | F10SMYD3DPP4 | |
| Hydrochloric Acid SCHEMBL14483114 | 0.70 | DPP4 (0.43) | PYGLDPP4 | |
| SCHEMBL6978650 | 0.66 | F10 (0.47) | F10KLKB1KMT2A | |
| SCHEMBL6981248 | 0.63 | F10 (0.54) | F10KMT2A | |
| SCHEMBL5622900 | 0.63 | PLAU (0.39) | F10DPP4 | |
| SCHEMBL6978513 | 0.62 | PLAU (0.63) | F10BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1012166-B1 | 1-AMINO-7-ISOQUINOLINE DERIVATIVES AS SERINE PROTEASE INHIBITORS | TULARIK LTD (GB) | 2003-10-29 | — | — | EP | disclosed |
| US-6420438-B1 | FOR THERAPY OF THROMBOTIC DISEASE, ASTHMA, EMPHYSEMA, CIRRHOSIS, ARTHRITIS, CARCINOMA, MELANOMA, RESTENOIS, ATHEROMA, TRAUMA, SHOCK AND REPERFUSION INJURY | TULARIK LIMITED (GB) | 2002-07-16 | — | — | US | disclosed |
| US-20020040144-A1 | 1-amino-7-isoquinoline derivatives as serine protease inhibitors | TULARIK LIMITED (GB) | 2002-04-04 | — | — | US | disclosed |
| US-6262069-B1 | 1-amino-7-isoquinoline derivatives as serine protease inhibitors | PROTHERICS MOLECULAR DESIGN LIMITED (GB) | 2001-07-17 | — | — | US | disclosed |
| EP-1012166-A1 | 1-AMINO-7-ISOQUINOLINE DERIVATIVES AS SERINE PROTEASE INHIBITORS | Protherics Molecular Design Limited (GB) | 2000-06-28 | — | — | EP | disclosed |
| WO-1999011657-A1 | 1-AMINO-7-ISOQUINOLINE DERIVATIVES AS SERINE PROTEASE INHIBITORS | PROTEUS MOLECULAR DESIGN LTD. (GB) | 1999-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020040144-A1 | 1-amino-7-isoquinoline derivatives as serine protease inhibitors | CTRL, HPN, CTSL | F10 1211/4885PRMT3 1254/4885SMYD3 3979/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.